Safety of percutaneous left atrial appendage closure with the amplatzer cardiac plug in patients with atrial fibrillation and contraindications to anticoagulation

Catheterization and Cardiovascular Interventions

Volumn 83, Issue 5, 2014, Pages 796-802

  Wiebe, Jens ^a   Bertog, Stefan ^a   Franke, Jennifer ^a   Wettstein, Olga ^a   Lehn, Katharina ^a   Hofmann, Ilona ^a   Vaskelyte, Laura ^a   Sievert, Horst ^a  

^a CARDIOVASCULAR CENTER FRANKFURT   (Germany)

Author keywords

coagulation; embolization; left atrial appendage closure

Indexed keywords

LIVER ENZYME; LOW MOLECULAR WEIGHT HEPARIN; PHENPROCOUMON; WARFARIN;

AGED; AMBULATORY CARE; AMPLATZER VASCULAR PLUG; ANTICOAGULATION; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; EPISTAXIS; FALLING; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HEMATOMA; HEMATURIA; HEMOPERICARDIUM; HUMAN; INCIDENCE; INTRAOCULAR HEMORRHAGE; LEFT ATRIAL APPENDAGE CLOSURE DEVICE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PATIENT SAFETY; PERCUTANEOUS LEFT ATRIAL APPENDAGE CLOSURE; RETROSPECTIVE STUDY; RISK ASSESSMENT; THROMBUS; TREATMENT CONTRAINDICATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

COAGULATION; EMBOLIZATION; LEFT ATRIAL APPENDAGE CLOSURE;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL APPENDAGE; ATRIAL FIBRILLATION; CARDIAC CATHETERIZATION; EQUIPMENT DESIGN; HEMORRHAGE; HUMANS; MALE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; STROKE; TIME FACTORS; TREATMENT OUTCOME; WARFARIN;

EID: 84899437827     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.25329     Document Type: Article

References (24)

1. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG,. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med 1995; 155: 469-473.
2. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE,. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The anticoagulation and risk factors in atrial fibrillation (atria) study. JAMA 2001; 285: 2370-2375.
3. Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS, D'Agostino RB, Massaro JM, Beiser A, Wolf PA, Benjamin EJ,. Lifetime risk for development of atrial fibrillation: The framingham heart study. Circulation 2004; 110: 1042-1046.
4. Wolf PA, Abbott RD, Kannel WB,. Atrial fibrillation as an independent risk factor for stroke: The framingham study. Stroke 1991; 22: 983-988.
5. Hart RG, Benavente O, McBride R, Pearce LA,. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: A meta-analysis. Ann Intern Med 1999; 131: 492-501.
6. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Kay GN, Le Huezey JY, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann LS, Smith SC Jr,., Priori SG, Estes NA III, Ezekowitz MD, Jackman WM, January CT, Page RL, Slotwiner DJ, Stevenson WG, Tracy CM, Jacobs AK, Anderson JL, Albert N, Buller CE, Creager MA, Ettinger SM, Guyton RA, Hochman JS, Kushner FG, Ohman EM, Tarkington LG, Yancy CW., 2011 accf/aha/hrs focused updates incorporated into the acc/aha/esc 2006 guidelines for the management of patients with atrial fibrillation: A report of the american college of cardiology foundation/american heart association task force on practice guidelines. Circulation 2011; 123: e269-367.
7. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P,; ESC Committee for Practice Guidelines (CPG), Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S,; Document Reviewers, Vardas P, Al-Attar N, Alfieri O, Angelini A, Blömstrom-Lundqvist C, Colonna P, De Sutter J, Ernst S, Goette A, Gorenek B, Hatala R, Heidbüchel H, Heldal M, Kristensen SD, Kolh P, Le Heuzey JY, Mavrakis H, Mont L, Filardi PP, Ponikowski P, Prendergast B, Rutten FH, Schotten U, Van Gelder IC, Verheugt FW,. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33: 2719-2747.
8. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L,. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
9. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM,. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891.
10. Holmes DR, Reddy VY, Turi ZG, Doshi SK, Sievert H, Buchbinder M, Mullin CM, Sick P,. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: A randomised non-inferiority trial. Lancet 2009; 374: 534-542.
11. Park JW, Leithauser B, Gerk U, Vrsansky M, Jung F,. Percutaneous left atrial appendage transcatheter occlusion (plaato) for stroke prevention in atrial fibrillation: 2-year outcomes. J Invasive Cardiol 2009; 21: 446-450.
12. Rodes-Cabau J, Champagne J, Bernier M,. Transcatheter closure of the left atrial appendage: Initial experience with the amplatzer cardiac plug device. Catheter Cardiovasc Interv 2010; 76: 186-192.
13. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ,. Validation of clinical classification schemes for predicting stroke: Results from the national registry of atrial fibrillation. JAMA 2001; 285: 2864-2870.
14. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ,. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The euro heart survey on atrial fibrillation. Chest 2010; 137: 263-272.
15. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY,. A novel user-friendly score (has-bled) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The euro heart survey. Chest 2010; 138: 1093-1100.
16. Waldo AL, Becker RC, Tapson VF, Colgan KJ,. Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation. J Am Coll Cardiol 2005; 46: 1729-1736.
17. Lip GY, Andreotti F, Fauchier L, Huber K, Hylek E, Knight E, Lane DA, Levi M, Marin F, Palareti G, Kirchhof P, Collet JP, Rubboli A, Poli D, Camm J,. Bleeding risk assessment and management in atrial fibrillation patients: A position document from the european heart rhythm association, endorsed by the european society of cardiology working group on thrombosis. Europace 2011; 13: 723-746.
18. Go AS, Hylek EM, Chang Y, Phillips KA, Henault LE, Capra AM, Jensvold NG, Selby JV, Singer DE,. Anticoagulation therapy for stroke prevention in atrial fibrillation: How well do randomized trials translate into clinical practice? JAMA 2003; 290: 2685-2692.
19. Ostermayer SH, Reisman M, Kramer PH, Matthews RV, Gray WA, Block PC, Omran H, Bartorelli AL, Della Bella P, Di Mario C, Pappone C, Casale PN, Moses JW, Poppas A, Williams DO, Meier B, Skanes A, Teirstein PS, Lesh MD, Nakai T, Bayard Y, Billinger K, Trepels T, Krumsdorf U, Sievert H,. Percutaneous left atrial appendage transcatheter occlusion (plaato system) to prevent stroke in high-risk patients with non-rheumatic atrial fibrillation: Results from the international multi-center feasibility trials. J Am Coll Cardiol 2005; 46: 9-14.
20. Park JW, Sievert H, Schillinger W, Lickfett L, Lopez-Minguez JR, Omran H, Valdes M, Hennen B, Walsh K, Ormerod O, Neuzil P, Schraeder R, Garcia E, Hildick-Smith D, Lezaun R,. Results of the Amplatzer Cardiac Plug European Multicenter Prospective Observational Study. JACC 2012 (suppl. B); 60: B27.
21. Bayard YL, Omran H, Neuzil P, Thuesen L, Pichler M, Rowland E, Ramondo A, Ruzyllo W, Budts W, Montalescot G, Brugada P, Serruys PW, Vahanian A, Piechaud JF, Bartorelli A, Marco J, Probst P, Kuck KH, Ostermayer SH, Buscheck F, Fischer E, Leetz M, Sievert H,. Plaato (percutaneous left atrial appendage transcatheter occlusion) for prevention of cardioembolic stroke in non-anticoagulation eligible atrial fibrillation patients: Results from the european plaato study. EuroIntervention 2010; 6: 220-226.
22. Reddy VY, Möbius-Winkler S, Miller MA, Neuzil P, Schuler G, Wiebe J, Sick P, Sievert H,. Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: The ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology). J Am Coll Cardiol 2013; 61: 2551-2556.
23. Lund J, Saraste A, Airaksinen KE,. Percutaneous left atrial appendage closure with minimal antithrombotic treatment in patients at very high risk of bleeding events. Thromb Res 2012; 130: e194-195.
24. Nakai T, Lesh MD, Gerstenfeld EP, Virmani R, Jones R, Lee RJ,. Percutaneous left atrial appendage occlusion (plaato) for preventing cardioembolism: First experience in canine model. Circulation 2002; 105: 2217-2222.